Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Ibrutinib improves event-free survival in early-stage CLL patients with certain genetic mutations but offers no overall survival benefit across all subgroups.

• Why it matters: Understanding which genetic factors influence treatment response is crucial for optimizing management of early-stage CLL, especially since current standards favor watch-and-wait.
• What they did: The study analyzed 515 patients in the CLL12 trial, comparing ibrutinib versus placebo, focusing on genetic subgroups and their impact on event-free and overall survival over a median follow-up of 69.3 months.
• The result: Ibrutinib significantly extended EFS in patients with U-IGHV, del(11q), +12, NOTCH1, ATM, and NFKBIE mutations, but not in those with del(17p) or TP53 mutations, highlighting its selective benefit and confirming watch-and-wait as standard care for high-risk early-stage CLL.